GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Ending Cash Position

Pet Pharm Biotech Co (ROCO:7762) Ending Cash Position : NT$181.8 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Ending Cash Position?

Pet Pharm Biotech Co's Ending Cash Position for the quarter that ended in Dec. 2024 was NT$181.8 Mil.

Pet Pharm Biotech Co's quarterly Ending Cash Position declined from Dec. 2023 (NT$168.5 Mil) to Jun. 2024 (NT$125.9 Mil) but then increased from Jun. 2024 (NT$125.9 Mil) to Dec. 2024 (NT$181.8 Mil).

Pet Pharm Biotech Co's annual Ending Cash Position increased from Dec. 2022 (NT$16.8 Mil) to Dec. 2023 (NT$168.5 Mil) and increased from Dec. 2023 (NT$168.5 Mil) to Dec. 2024 (NT$181.8 Mil).


Pet Pharm Biotech Co Ending Cash Position Historical Data

The historical data trend for Pet Pharm Biotech Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Ending Cash Position Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24
Ending Cash Position
16.76 168.49 181.79

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Ending Cash Position - 31.81 168.49 125.87 181.79

Pet Pharm Biotech Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pet Pharm Biotech Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=168.485+13.301
=181.8

Pet Pharm Biotech Co's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=125.869+55.917
=181.8


Pet Pharm Biotech Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Pet Pharm Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines